Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.
Adelina OrellanaPablo García GonzálezSergi ValeroLaura MontrrealItziar De RojasIsabel HernándezMaitee Rosende-RocaLiliana VargasJuan Pablo TartariEster Esteban-De AntonioUrszula BojarynLeire NarvaizaEmilio Alarcón-MartínMontserrat AlegretDaniel AlcoleaAlberto LleóLluís TárragaVanesa PytelAmanda CanoMarta MarquiéMercè BoadaAgustin RuizPublished in: International journal of molecular sciences (2022)
We established CLEIA and ELISA internal cutoffs to discriminate AD patients from amyloid-negative SCD individuals. The results obtained by both methods are not interchangeable but show good agreement. CLEIA is a good and faster alternative to manual ELISA for providing AT(N) classification of our patients. AT(N) categories have an impact on disease progression. AT(N) classifiers increase the certainty of the MCI prognosis, which can be instrumental in managing real-world MCI subjects.